High grade non muscle invasive bladder cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

NMIBC, also known as non-muscle invasive bladder cancer, is a subtype of bladder carcinoma. Urinary bladder cancer is also known as "superficial" bladder cancer. The malignancy has not affected any of the muscle tissue visible inside the bladder in NMIBC. Patients who typically experience hematuria or voiding symptoms undergo a cystoscopy to determine whether they have bladder cancer. The tumor(s) are biopsied, removed, and cross-sectional imaging is used to check for metastases during the procedure. NMIBC continues to pose a significant health risk due to its progression and recurrence, and the surgical resources and expertise needed for TURBT prevent it from being widely available to meet clinical needs.

Description

NMIBC, also known as non-muscle invasive bladder cancer, is a subtype of bladder carcinoma. Urinary bladder cancer is also known as "superficial" bladder cancer. The malignancy has not affected any of the bladder's muscle tissue as seen in NMIBC. A different subtype of bladder cancer, known as muscle-invasive bladder cancer (MIBC), is distinguished by the presence of a tumor within the muscular wall of the bladder. The bladder as a whole is the site of the majority of malignancies affecting the urinary system. NMIBC is present in about 70% of bladder cancer patients who have recently received a diagnosis. Bladder cancer occurs more frequently in men than in women, almost three times more frequently. The majority of people in this group are aged 50 to 70. NMIBC is a group of tumors with a very diverse biological behaviour and natural history. After total endoscopic resection, up to 80% of patients will experience tumor recurrence, with 2-50% displaying stage advancement. On the other hand, patients are rarely in danger from low-grade Ta tumors despite having a high risk of recurrence. High-grade T1 tumors are at the other end of the spectrum and grow and die quickly. How effectively NMIBC is treated depends on the biological characteristics of the tumor and properly selected and applied treatments.

High grade non muscle invasive bladder cancer (Epidemiology)

About 80,000 new cases of bladder cancer are diagnosed in the United States each year, and urothelial carcinomas account for 90% of these cases. With a median age of 70, the presenters were mostly male. Chemical carcinogens from occupational exposure and tobacco smoke, such as aromatic amines, polycyclic aromatic hydrocarbons (PAHs), and benzenes, are the strongest known risk factors for bladder cancer in the United States. It is also becoming more widely acknowledged that other environmental and genetic risk factors play a role. Patients who frequently experience hematuria or voiding symptoms can be diagnosed with bladder cancer using a cystoscopy. The tumor(s) are biopsied, removed, and cross-sectional imaging is used to check for metastases during the procedure.

High grade non muscle invasive bladder cancer -Current Market Size & Forecast Trends

The market for high-grade non-muscle invasive bladder cancer (NMIBC) is projected to experience significant growth, with the global non-muscle invasive bladder cancer therapeutics market estimated at approximately USD 1.45 billion in 2023. This market is expected to expand notably, reaching around USD 10.9 billion by 2031, reflecting a compound annual growth rate (CAGR) of approximately 21.4% from 2024 to 2034. The growth is driven by increasing incidence rates of bladder cancer, advancements in treatment options including immunotherapy and targeted therapies, and rising healthcare expenditures focused on improving patient outcomes. North America is expected to dominate the market due to its advanced healthcare infrastructure and significant investments in research and development for bladder cancer treatments. The Asia-Pacific region is anticipated to grow rapidly, attributed to a rising prevalence of bladder cancer and improved access to innovative therapies. Overall, the high-grade NMIBC market is well-positioned for robust expansion through 2035, supported by ongoing innovations in treatment and increased awareness of the disease.

NMIBC continues to pose a serious health risk due to its progression and recurrence, and TURBT is not widely available to meet clinical needs due to the surgical resources and expertise needed. Despite the use of intravesical immuno- and chemotherapies as adjuvants or salvage to halt the progression and recurrence of NMIBC, the full recovery is still not achieved. Recent advancements in regenerative therapies, such as stem cells and PRP, also point to potential therapeutic opportunities because of their accessibility, simplicity, and long-term safety; however, more thorough research and clinical trials are required to optimize the procedure, doses, clinical safety, and effectiveness for these alternatives. The few candidates that have the potential to address the various unmet needs include Cretostimogene grenadenorepvec (CG Oncology), Picibanil biosimilar (Protara Therapeutics), Oportuzumab monatox (Sesen Bio), APL 1202 (Asieris Pharmaceuticals), and others.

Report Highlights

High grade non muscle invasive bladder cancer - Current Market Trends

High grade non muscle invasive bladder cancer - Current & Forecasted Cases across the G8 Countries

High grade non muscle invasive bladder cancer - Market Opportunities and Sales Potential for Agents

High grade non muscle invasive bladder cancer - Patient-based Market Forecast to 2035

High grade non muscle invasive bladder cancer - Untapped Business Opportunities

High grade non muscle invasive bladder cancer - Product Positioning Vis-a-vis Competitors' Products

High grade non muscle invasive bladder cancer - KOLs Insight